Skip to main content
Equibles
HSCS logo

HSCS · HeartSciences Inc.

Track HSCS — free

Use HSCS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HSCS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.19 +0.12 (+3.91%)
Rebalance outlook locked
Going-concern doubt — flagged Sep 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Sep 14, 2026
Market Cap
$14.74M
Shares
4.80M
Volume · Oct 20 42.82K Avg daily vol (3M) 157.53K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.07 Open$2.97 Day$2.93–3.16 52W close$1.67–5.20 Avg vol 30d223K Short int28K · 0.6% float · 1.0d Short vol76% Last earningsMar 16, 2026 DataJun 2022–Oct 2026 Filing10-Q · Sep 14

Up next

Latest filing: 10-Q
filed Sep 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4,519
Trailing 12 months
Net income (TTM)
−$10.26M
Trailing 12 months
Revenue growth YoY
+10.5%
Year over year
Operating margin
-209,733.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$29,906
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+203.1%
Year over year · more shares
Price change (1Y)
-7.8%
Trailing year
Short interest
0.6%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $3,900 −$1.75M '24 Q2 ▲653.8% $14,700 −$1.64M '24 Q3 ▼100% $0 −$2.54M '25 Q3 · $1,900 −$2.05M '26 Q1 · $2,419 −$2.35M '26 Q2 · $0 −$1.99M '26 Q3 · $0 −$2.75M '26 Q4* LATEST ▲10.5% $2,100 −$3.17M '27 Q1

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg −10%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 40%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −34%
trailing
6-month return +54%
trailing
YTD return −1%
this year
Relative strength +46%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.58% of float · ▼ -29.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Squeeze score 32
low risk · 0–100
Fundamentals
Fair
Revenue growth −1%
Y/Y
Gross margin 59%
expanding
EPS growth +50%
Y/Y
Free cash flow $-7.4M
Quant / Vol
risk profile
Very High
Volatility 107%
annualized · 1-yr
Max drawdown −54%
past year
ATR 13.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 29, 2026
Run-rate Adjusted EBITDA · run-rate, once new machines are delivered and hashing (at Zcash Non-GAAP at least $50M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
−10% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
40% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.58% of float · ▼ -29.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 40% Range high $5
vs 200-day avg +13% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HSCS
HeartSciences Inc.
this stock
$14.74M -0.6% -0.7% — 0.6%
ABT
Abbott Laboratories
 $179.20B -16.9% +5.7% 33.3 0.8%
MDT
Medtronic plc
 $118.67B -3.4% +8.4% 22.9 3.1%
SYK
Stryker Corp
 $114.28B -15.2% +11.2% 30.9 1.5%
BSX
Boston Scientific Corp
 $66.02B -52.8% +12.5% 18.4 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
17
% held
12.8%
Net QoQ
-67.1K sh
Top holder
Clear Street Group Inc.
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
27.9K
Days to cover
1.0d
Change
-11.9K sh
View
Short Volume
Short vol %
76%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$4.9K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
49.7%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.3K
Net income (FY)
$-9.1M
EPS diluted
$-9.34
View
Filings
SEC Filings
Latest
DEFA14A
Filed
Oct 19, 2026
This year
89

HeartSciences and Fortitude entered a definitive merger agreement to combine in an all-stock transaction; Fortitude is a vertically-integrated digital asset mining platform anchored in Zcash, while HeartSciences is an AI-powered medical technology company.

View
Proposed Sales
Value
$15.7K
Shares
4.4K
Filed
Jul 29, 2025
View
Exempt Offerings
Offering
$935.0K
Filed
Dec 7, 2023
View
Earnings & Events
Webcasts
Last webcast
Mar 16, 2026
View

Performance

5D 20D 120D MTD YTD
HSCS -7.0% -34.4% +53.5% -26.6% -0.7%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -5.5% -33.5% +45.8% -27.1% -13.1%
Key facts CIK 1468492 CUSIP 42254E302 Visit website Investor relations